Translation and automation hurdles for cell therapies

Cell & Gene Therapy Insights 2021; 7(11), 1605–1612


Published: 9 December 2021
Jenny A Prange, Beatrix Rauch-Schmid

Jenny A Prange as co-founder and CSO of MUVON, Jenny is coordinating all research activities aiming towards the improvement of cell production and the therapy in general and manages the GMP production. She initially joined the team early in 2017 for the setup of the GMP-compliant production of muscle precursor as part of the MUSIC project. Jenny obtained her PhD in Integrative Molecular Medicine from the University of Zurich and gained research experience during her studies at Roche in Switzerland, Novartis in the US, and the Federal Research Institute for Animal Health in Germany. Jenny holds a Diplôme d’Ingénieure in Biotechnology from the Ecole supérieure de Biotechnologie de Strasbourg as well as a Master’s degree in Biotechnology and Therapeutic Innovation from the University of Strasbourg.

Beatrix Rauch-Schmid - Innovation Manager - She finished her biotechnology studies 2006 with a diploma thesis in tissue engineering on the regeneration of cartilage at the fzmb in Germany and broadened her R&D experience at the Australian ANU and many years at Roche. She finalized her MAS-MTEC Studies (ETH) at the Chair of Innovation. Beatrix joined MUVON Therapeutics in the beginning of 2021 and is responsible for the coordination of innovation projects such as automating the production process.